The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

gabexate     ethyl4-[6- (diaminomethylideneamino) hexano...

Synonyms: Gabexato, Gabexatum, Tocris-1798, Gabexate (INN), Gabexate [INN], ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of gabexate


High impact information on gabexate


Chemical compound and disease context of gabexate

  • Injections of gabexate and proglumide from initiation of CDE diet (before induction of pancreatitis) increased survival from 37% (diet alone) to 85 and 75%, respectively, and also ameliorated histological alterations and increases in serum amylase concentration and pancreatic activated trypsin [4].
  • CR 1409, a glutaramic acid derivative with competitive cholecystokinin-antagonistic activity, was administered IP and evaluated in comparison with proglumide (the model CCK-receptor antagonist), gabexate (protease inhibitor) and PGE2 (cytoprotective) on two different models of experimental pancreatitis [7].
  • CONCLUSION: The administration of low- and high-dose ulinastatin has similar effects to high-dose gabexate in the prevention of post-ERCP pancreatitis [8].
  • While octreotide was confirmed to be ineffective, somatostatin and gabexate seem to be the best for the prevention of post-ERCP pancreatitis, but both can present some limits such as unreported sample size calculation in the statistical analysis for somatostatin studies and lack of widespread commercial availability for gabexate [9].

Biological context of gabexate


Anatomical context of gabexate


Associations of gabexate with other chemical compounds


Gene context of gabexate


Analytical, diagnostic and therapeutic context of gabexate


  1. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. Cavallini, G., Tittobello, A., Frulloni, L., Masci, E., Mariana, A., Di Francesco, V. N. Engl. J. Med. (1996) [Pubmed]
  2. Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor. Niederau, C., Crass, R.A., Silver, G., Ferrell, L.D., Grendell, J.H. Gastroenterology (1988) [Pubmed]
  3. Gabexate as a therapy for disseminated intravascular coagulation. Umeki, S., Adachi, M., Watanabe, M., Yaji, S., Soejima, R. Arch. Intern. Med. (1988) [Pubmed]
  4. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. Niederau, C., Liddle, R.A., Ferrell, L.D., Grendell, J.H. J. Clin. Invest. (1986) [Pubmed]
  5. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Pande, H., Thuluvath, P. Drugs (2003) [Pubmed]
  6. Gabexate and camostat, synthetic proteinase inhibitors, as direct inducing factors of water and bicarbonate secretion in the isolated and blood-perfused dog pancreas. Horiuchi, A., Iwatsuki, K., Yonekura, H., Ren, L.M., Chiba, S. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  7. Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice. Makovec, F., Bani, M., Cereda, R., Chistè, R., Revel, L., Rovati, L.C., Setnikar, I., Rovati, L.A. Peptides (1986) [Pubmed]
  8. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. Fujishiro, H., Adachi, K., Imaoka, T., Hashimoto, T., Kohge, N., Moriyama, N., Suetsugu, H., Kawashima, K., Komazawa, Y., Ishimura, N., Ishihara, S., Amano, Y., Kinoshita, Y. J. Gastroenterol. Hepatol. (2006) [Pubmed]
  9. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? Mariani, A. JOP (2003) [Pubmed]
  10. Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Okumura, K., Kiyohara, Y., Komada, F., Iwakawa, S., Hirai, M., Fuwa, T. Pharm. Res. (1990) [Pubmed]
  11. Results of treating severe acute pancreatitis with gabexate is associated with neutrophil apoptosis activity. Chiu, D.F., Chen, J.C., Chen, H.M., Ng, C.J., Shyr, M.H., Chen, M.F. Hepatogastroenterology (2003) [Pubmed]
  12. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Di Francesco, V., Mariani, A., Angelini, G., Masci, E., Frulloni, L., Talamini, G., Passaretti, S., Testoni, P., Cavallini, G. Dig. Dis. Sci. (2002) [Pubmed]
  13. Effects of gabexate, a protease inhibitor, on smooth muscle of guinea-pig stomach fundus. Hirano, K., Nakazawa, S., Tomita, T. Pharmacol. Toxicol. (1995) [Pubmed]
  14. The effect of protease inhibitor on reperfusion injury after unilateral pulmonary ischemia. Horiguchi, T., Harada, Y. Transplantation (1993) [Pubmed]
  15. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Masci, E., Cavallini, G., Mariani, A., Frulloni, L., Testoni, P.A., Curioni, S., Tittobello, A., Uomo, G., Costamagna, G., Zambelli, S., Macarri, G., Innocenti, P., Dragonetti, C. Am. J. Gastroenterol. (2003) [Pubmed]
  16. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Andriulli, A., Clemente, R., Solmi, L., Terruzzi, V., Suriani, R., Sigillito, A., Leandro, G., Leo, P., De Maio, G., Perri, F. Gastrointest. Endosc. (2002) [Pubmed]
WikiGenes - Universities